kabutan

Fuso Pharmaceutical Industries,Ltd., The Current Fiscal Year Ordinary Profit Revised Upward by 61%, Dividend Revised Upward by 2 yen

Mon Nov 11, 2024 1:40 pm JST Earnings

4538 Fuso Pharmaceutical Industries,Ltd. 【J-GAAP】

Earnings Report

Fuso Pharmaceutical Industries,Ltd. <4538> [TSE-P] announced its financial results in the afternoon session on November 11th (13:40). The ordinary profit (non-consolidated) for the cumulative second quarter of the fiscal year ending March 2025 (April to September) expanded to 2.14 billion yen, an increase of 95.2% compared to the same period last year.

In addition, the full-year ordinary profit has been revised upward by 60.9%, from the previous forecast of 2.3 billion yen to 3.7 billion yen (compared to 1.86 billion yen in the previous period), increasing the growth rate from 23.1% to 98.1%.

Based on the first-half performance announced by the company and the full-year plan, our calculation indicates that the ordinary profit for the October to March period (second half) is expected to surge by 2.0 times that of the same period last year, reaching 1.55 billion yen.

In light of the strong performance, the company has increased its planned annual dividend for the current fiscal year from the original plan of 80 yen to 82 yen (compared to 70 yen in the previous period).

In the most recent three-month period, from July to September (2Q), the ordinary profit surged to 2.8 times that of the same period last year, reaching 1.23 billion yen. The operating profit margin significantly improved from 3.7% in the same period last year to 8.5%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2022 25,371 1,285 1,399 1,018 116.1 63.2 Nov 9, 2022 J-GAAP
Apr - Sep, 2023 27,424 1,099 1,098 717 82.2 58.8 Nov 10, 2023 J-GAAP
Apr - Sep, 2024 29,739 2,434 2,143 1,535 179.8 57.9 Nov 11, 2024 J-GAAP
YoY +8.4% +121.5% +95.2% +114.1% +118.7%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 Guidance 29,700 2,400 2,100 1,500 175.6 40 Nov 1, 2024 J-GAAP
Apr - Sep, 2024 Results 29,739 2,434 2,143 1,535 179.8 40 Nov 11, 2024 J-GAAP
Revision Rate +0.1% +1.4% +2.0% +2.3% +2.4%

Guidance Update

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Prev 57,000 2,600 2,300 1,700 199.0 80 May 10, 2024 J-GAAP
Mar, 2025 New 60,000 4,000 3,700 2,600 304.4 82 Nov 11, 2024 J-GAAP
Revision Rate +5.3% +53.8% +60.9% +52.9% +52.9%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 27,983 865 770 660 76.7 35 May 10, 2024 J-GAAP
Oct - Mar, 2024 Guidance 30,261 1,566 1,557 1,065 124.7 42 Nov 11, 2024 J-GAAP
YoY +8.1% +81.0% +102.2% +61.4% +62.6%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 51,015 2,206 2,215 1,605 183.1 70 May 10, 2023 J-GAAP
Mar, 2024 55,407 1,964 1,868 1,377 160.0 70 May 10, 2024 J-GAAP
Mar, 2025 Guidance 60,000 4,000 3,700 2,600 304.4 82 Nov 11, 2024 J-GAAP
YoY +8.3% +103.7% +98.1% +88.8% +90.3%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 13,917 510 440 238 27.3 3.7 Nov 10, 2023 J-GAAP
Oct - Dec, 2023 15,406 744 731 510 59.0 4.8 Feb 13, 2024 J-GAAP
Jan - Mar, 2024 12,577 121 39 150 17.4 1.0 May 10, 2024 J-GAAP
Apr - Jun, 2024 14,622 1,150 909 632 74.1 7.9 Aug 8, 2024 J-GAAP
Jul - Sep, 2024 15,117 1,284 1,234 903 105.7 8.5 Nov 11, 2024 J-GAAP
YoY +8.6% +151.8% +180.5% +279.4% +287.6%

Related Articles